Loading...
Loading...
Pneumonic tularemia is a rare but potentially life-threatening form of tularemia caused by Francisella tularensis, typically acquired through inhalation of contaminated aerosols or secondary to hematogenous spread. [1-2] This form has the highest mortality rate (up to 60% if untreated) and requires prompt recognition and treatment. [2]
The following figure illustrates the various transmission routes and clinical manifestations of tularemia:
Key HPI questions:
• Onset and duration of symptoms (typically 3-5 days incubation, range 1-14 days) [4]
• Fever pattern and severity (38.0-41.5°C) [4]
• Respiratory symptoms: cough (often with scant sputum), chest pain, dyspnea [1][5]
• Constitutional symptoms: fatigue, headache, myalgias, malaise [1][4]
Symptom characterization:
• Fever is typically high-grade and acute in onset [4]
• Cough is usually nonproductive or with minimal sputum [6]
• Chest pain may be pleuritic [5]
Timing, triggers, severity, progression:
• Symptoms develop 1-14 days after exposure (average 3-5 days) [4]
• Can progress rapidly to severe pneumonia and respiratory failure [7]
• May present initially as systemic illness without prominent respiratory signs [7]
Associated symptoms:
• Headache, myalgias, malaise, chills [4]
• Abdominal pain, nausea, vomiting (especially in typhoidal form) [7]
• Pharyngitis may be present [4]
Important negatives:
• Absence of skin ulcers or lymphadenopathy (distinguishes from ulceroglandular form) [7]
• No conjunctival involvement [7]
Red flag symptoms/signs:
• High fever with rapid clinical deterioration [2]
• Respiratory distress or failure [7]
• Septic shock presentation [4]
• Altered mental status [7]
Features suggesting life-threatening pathology:
• Pneumonic and typhoidal forms have highest mortality [2]
• Rapid progression to severe pneumonia [7]
• Signs of sepsis or multi-organ failure [7]
Indications for urgent escalation:
• Respiratory distress requiring oxygen support
• Hemodynamic instability
• Suspected bioterrorism exposure (requires immediate public health notification) [8]
Relevant medication contributors:
• Beta-lactam antibiotics are ineffective and should be avoided [9-10]
• Anti-TNF agents increase risk of severe infection [6]
• Immunosuppressive medications increase severity risk [6]
Common treatments:
• First-line for severe disease: Gentamicin 1.5 mg/kg IV q8h or streptomycin 15 mg/kg IM q12h [11]
• First-line for mild-moderate disease: Ciprofloxacin 750 mg PO BID or levofloxacin 500 mg PO daily [8][11]
• Alternative: Doxycycline 100 mg PO BID [11]
Contraindicated medications:
• Beta-lactam antibiotics (penicillins, cephalosporins) [9-10]
• Most macrolides (except azithromycin in specific European strains) [10]
Medication interactions or cautions:
• Fluoroquinolones: avoid in pregnancy and young children due to musculoskeletal concerns [10]
• Aminoglycosides: monitor renal function and hearing [11]
Dietary triggers or recommendations:
• No specific dietary restrictions during acute illness
• Maintain adequate nutrition during prolonged illness
Hydration considerations:
• Ensure adequate hydration, especially with fever
• Monitor fluid balance in severe cases
Important ROS questions:
• Respiratory: cough, dyspnea, chest pain, hemoptysis
• Constitutional: fever, chills, night sweats, weight loss
• GI: abdominal pain, nausea, vomiting, diarrhea
• Neurologic: headache, altered mental status
• Skin: rash, ulcers, lymphadenopathy
High-yield associated systems:
• Hepatic involvement (elevated transaminases common) [4]
• Pleural involvement (effusions) [1][12]
Important collateral information:
• Recent outdoor activities in endemic areas [1][5]
• Animal exposure (rabbits, rodents, cats) [13]
• Tick bites or arthropod exposure [5]
• Travel to rural areas [1][5]
• Occupational exposure (veterinarians, hunters, laboratory workers)
Relevant hereditary conditions:
• Immunodeficiency syndromes
• Family history of unusual infections
Social context:
• Rural residence or activities [1][5]
• Hunting, trapping, or animal handling [13]
• Laboratory work with potential F. tularensis exposure
Major epidemiologic risk factors:
• Rural residence or outdoor activities [1][5]
• Contact with rabbits, rodents, or other small mammals [13]
• Tick or deerfly bites [5]
• Drinking untreated water [3]
• Laboratory exposure [8]
Lifestyle contributors:
• Hunting, trapping, skinning animals [13]
• Gardening, lawn mowing in endemic areas [3]
• Camping in endemic areas
Comorbidities increasing risk:
• Immunosuppression (including anti-TNF therapy) [6]
• Advanced age [12]
• Chronic medical conditions [12]
Most important alternative diagnoses:
• Community-acquired pneumonia (bacterial, viral, atypical)
• Tuberculosis [10]
• Lung cancer or lymphoma [1]
• Sarcoidosis [6]
• Histoplasmosis or other endemic mycoses
Dangerous cannot-miss diagnoses:
• Pneumonic plague
• Anthrax (inhalational)
• Severe acute respiratory syndrome
• Pneumonic tularemia in bioterrorism context [8]
Mimics and distinguishing features:
• vs. Tuberculosis: Tularemia has more acute onset, less cavitation [10]
• vs. Lung cancer: Tularemia has fever, acute onset, exposure history [1]
• vs. CAP: Tularemia often has mediastinal lymphadenopathy [1][12]
Relevant prior conditions:
• Previous tularemia infection (provides some immunity)
• Immunocompromising conditions
• Chronic lung disease
Previous episodes:
• Prior tick-borne illnesses
• Previous pneumonias
Surgical history:
• Thoracic procedures
• Immunosuppressive procedures
Chronic illnesses impacting management:
• Renal disease (affects antibiotic dosing) [11]
• Liver disease
• Heart failure
Key exam findings:
• Fever (often high-grade 38-41.5°C) [4]
• Tachypnea, tachycardia
• Pulmonary findings may be minimal early in disease [7]
Vital sign abnormalities:
• High fever [4]
• Tachycardia, tachypnea
• Hypotension in severe cases [7]
Focused exam maneuvers:
• Complete pulmonary examination
• Lymph node examination (cervical, axillary, inguinal)
• Skin examination for ulcers or rashes
• Oropharyngeal examination
Expected vs concerning findings:
• Expected: Fever, mild respiratory findings initially [7]
• Concerning: Respiratory distress, altered mental status, hypotension [7]
Recommended labs:
• Complete blood count (usually normal or slightly elevated WBC) [4]
• Comprehensive metabolic panel
• Liver function tests (often elevated transaminases) [4]
• Blood cultures (low sensitivity ~10%) [6]
• Respiratory cultures if productive sputum
Expected abnormalities:
• Normal or slightly elevated WBC with normal differential [4]
• Elevated hepatic transaminases [4]
• Elevated inflammatory markers (ESR, CRP)
Labs used to rule out dangerous conditions:
• Blood cultures to rule out other bacterial pneumonia
• Sputum cultures and stains
• Procalcitonin may be elevated
Monitoring parameters:
• Renal function (if using aminoglycosides) [11]
• Liver function
• Complete blood count
First-line imaging:
• Chest X-ray: may show patchy infiltrates, hilar lymphadenopathy, pleural effusion [4][7]
Gold standard imaging:
• Chest CT: consistently shows mediastinal lymphadenopathy and pulmonary nodules [1]
• May show subpleural micronodules or pleural effusion [1]
• Subpleural round consolidations are characteristic [12]
Important imaging findings:
• Mediastinal lymphadenopathy (very common) [1][12]
• Pulmonary nodules or consolidations [1]
• May mimic malignancy on PET scan [1]
When imaging is unnecessary:
• Chest imaging is essential for suspected pneumonic tularemia
Diagnostic scoring systems:
• No specific scoring systems available
Point-of-care tests:
• None available
Procedures or specialty tests:
• Bronchoscopy with EBUS-TBNA may be performed [5]
• CT-guided biopsy (shows necrotizing granulomatous inflammation) [1][5]
ECG findings:
• Generally not specific for tularemia
• May show sinus tachycardia
Indications for ECG:
• Severe illness with hemodynamic compromise
• Elderly patients or those with cardiac risk factors
Clinical summary:
• Pneumonic tularemia is a rare but serious form of tularemia with high mortality if untreated [2]
• Often presents with nonspecific symptoms initially [1]
• Imaging typically shows mediastinal lymphadenopathy and pulmonary nodules [1][12]
Severity stratification:
• Mild-moderate: Stable vital signs, minimal respiratory distress
• Severe: Respiratory distress, hemodynamic instability, sepsis [2]
Typical vs atypical presentations:
• Typical: Acute febrile illness with respiratory symptoms and exposure history
• Atypical: May present as systemic illness without prominent respiratory signs [7]
Complications to consider:
• Respiratory failure [7]
• Septic shock [4]
• Treatment failure or relapse [9]
Initial stabilization:
• Supportive care for respiratory distress
• Fluid resuscitation if hypotensive
• Oxygen support as needed
Medications and dosing:
• Severe disease: Gentamicin 1.5 mg/kg IV q8h or streptomycin 15 mg/kg IM q12h [11]
• Mild-moderate disease: Ciprofloxacin 750 mg PO BID or levofloxacin 500 mg PO daily [8][11]
• Alternative: Doxycycline 100 mg PO BID [11]
• Duration: 10-14 days for severe cases, 14-21 days for mild-moderate [9][11]
Outpatient vs inpatient treatment:
• Inpatient: Severe disease, respiratory distress, hemodynamic instability
• Outpatient: Mild disease with reliable follow-up
Follow-up management:
• Monitor for treatment response
• Watch for complications or relapse [9]
Admission criteria:
• Severe pneumonia or respiratory distress
• Hemodynamic instability
• Inability to tolerate oral medications
• Concern for complications
Discharge criteria:
• Stable vital signs
• Tolerating oral medications
• Reliable follow-up available
• No signs of complications
Observation indications:
• Borderline cases with mild respiratory symptoms
• Elderly patients or those with comorbidities
Specialist consultation triggers:
• Infectious disease consultation for severe cases
• Pulmonology if respiratory failure
• ICU consultation for septic shock
Follow-up timing:
• 48-72 hours for outpatients to assess response
• Weekly follow-up until resolution
Symptoms requiring immediate reassessment:
• Worsening respiratory distress
• High fever despite treatment
• Signs of sepsis or shock
• Inability to tolerate medications
Patient counseling points:
• Complete full antibiotic course [9]
• Expect gradual improvement over days to weeks
• Avoid beta-lactam antibiotics [9-10]
• Report worsening symptoms immediately
Expected recovery course:
• Fever typically resolves within 24-115 hours depending on severity [12]
• Complete recovery may take weeks
• Relapse rates 5-15% depending on antibiotic choice [10]
1. Pulmonary Tularemia: A Diagnosis Not to Overlook. — Zaghdoudi A, Robin F, Moulinie J, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
2. Pulmonary Tularemia: A Diagnosis Not to Overlook. — Zaghdoudi A, Robin F, Moulinie J, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
3. Pulmonary Tularemia: A Diagnosis Not to Overlook. — Zaghdoudi A, Robin F, Moulinie J, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
4. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. — Antonello RM, Giacomelli A, Riccardi N. European Journal of Internal Medicine. 2025.
5. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. — Antonello RM, Giacomelli A, Riccardi N. European Journal of Internal Medicine. 2025.
6. Going Down the Rabbit Hole. — Burdick KJ, Ealick W, Vargas Acevedo H, Sectish TC, Sandora TJ. The New England Journal of Medicine. 2024.
7. Going Down the Rabbit Hole. — Burdick KJ, Ealick W, Vargas Acevedo H, Sectish TC, Sandora TJ. The New England Journal of Medicine. 2024.
8. Tick-Borne Diseases in the United States. — Spach DH, Liles WC, Campbell GL, et al. The New England Journal of Medicine. 1993.
9. Tick-Borne Diseases in the United States. — Spach DH, Liles WC, Campbell GL, et al. The New England Journal of Medicine. 1993.
10. Thoracic Manifestations of Tularaemia: A Case Series. — Vacca M, Wilhelms B, Zange S, et al. Infection. 2024.
11. Thoracic Manifestations of Tularaemia: A Case Series. — Vacca M, Wilhelms B, Zange S, et al. Infection. 2024.
12. Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis. — Schwarzová V, Schwarz J, Mitrová K, et al. Pediatric Pulmonology. 2023.
13. Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis. — Schwarzová V, Schwarz J, Mitrová K, et al. Pediatric Pulmonology. 2023.
14. Tularemia as a Biological Weapon: Medical and Public Health Management. — Dennis DT, Inglesby TV, Henderson DA, et al. The Journal of the American Medical Association. 2001.
15. Tularemia as a Biological Weapon: Medical and Public Health Management. — Dennis DT, Inglesby TV, Henderson DA, et al. The Journal of the American Medical Association. 2001.
16. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2025.
17. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2025.
18. Tularemia Treatment: Experimental and Clinical Data. — Maurin M, Pondérand L, Hennebique A, et al. Frontiers in Microbiology. 2023.
19. Tularemia Treatment: Experimental and Clinical Data. — Maurin M, Pondérand L, Hennebique A, et al. Frontiers in Microbiology. 2023.
20. Tularaemia: Clinical Aspects in Europe. — Maurin M, Gyuranecz M. The Lancet. Infectious Diseases. 2016.
21. Tularaemia: Clinical Aspects in Europe. — Maurin M, Gyuranecz M. The Lancet. Infectious Diseases. 2016.
22. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
23. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
24. Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones. — Widerström M, Mörtberg S, Magnusson M, Fjällström P, Johansson AF. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
25. Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones. — Widerström M, Mörtberg S, Magnusson M, Fjällström P, Johansson AF. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
26. Hunting for Tularaemia - A Review of Cases in North Carolina. — Rimawi RH, Shah KB, Chowdhary RA, Cook PP. Zoonoses and Public Health. 2015.
27. Hunting for Tularaemia - A Review of Cases in North Carolina. — Rimawi RH, Shah KB, Chowdhary RA, Cook PP. Zoonoses and Public Health. 2015.